← All trials
NCT04886765
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Nov 30, 2023
- Completion date
- May 31, 2024
- First posted
- May 14, 2021
- Last posted
- May 14, 2021
- Enrollment
- 238
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AlaMab Therapeutics (Shanghai) Inc.Lead sponsor
- Shijiazhuang Pharma Group (CSPC)Collaborator
- Sun Yat-Sen UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.